Race Oncology (ASX:RAC) Executes $8.6m Contract for Phase 1 RC220 Trial
Contract Details
Race Oncology has executed a $8.6 million contract with George Clinical International to support the RAC-010 Phase 1 trial of RC220 bisantrene in combination with doxorubicin. The trial will involve up to 53 patients across Australia, Hong Kong, and South Korea, focusing on safety, pharmacokinetics, and initial clinical data.
Study Overview
The open-label Phase 1 trial will determine the maximum tolerated combined dose of RC220 and doxorubicin, assess cardioprotective and anticancer efficacy, and explore the effects on various clinical biomarkers, including m6A RNA. The Bayesian design of the trial allows for greater flexibility and speed in execution.
Executive Comments
Race Chief Executive Officer, Dr Daniel Tillett, stated, “This work order agreement with George Clinical is a significant milestone for Race. Bringing RC220 to the clinic as a new treatment to potentially protect patients from the heart damage caused by anthracyclines like doxorubicin, while also improving the treatment of their cancer is groundbreaking. I wish to thank George Clinical and the entire Race clinical team for their hard work and dedication in establishing this agreement.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.